Back to search results

OLIGO-SWIFT: Faster SBRT for Oligometastatic Cancer

This study is for people with oligometastatic cancer, meaning cancer that has spread to up to five spots in the body. Doctors often recommend stereotactic body radiation therapy (SBRT) for these spots, but planning for SBRT can take a long time. This study is testing a "simulation-free workflow" using existing scans (CTs, PET/CTs, or MRIs) and a special online planning system called Ethos. The goal is to make SBRT planning faster so you can start treatment sooner. Participants will receive SBRT in up to five sessions over one to two weeks. The study wants to see if this faster approach is practical and accurate in a real-world setting. This study is currently unclear on its recruitment status.

Study design
This is an interventional study with a planned enrollment of 15 participants. It is testing a new way to deliver SBRT.
What's involved
You would receive SBRT in up to five sessions, delivered daily or every other day, over one to two weeks.
Compensation
Not stated in the trial record.
Follow-up
The primary goals of this study are measured up to two weeks, which is the timeframe of the SBRT treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07079098

Trial of Oligometastasis SBRT With Immediate, Simulation-Free Treatment Delivery (OLIGO-SWIFT)

Recruiting
PHASE1Ages 18+InterventionalTreatment
Case Comprehensive Cancer Center
~15 participants
Updated 2026-03-03 on ClinicalTrials.gov
What's tested:Simulation-free workflowSBRT

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Feasibility of a simulation-free adaptive radiotherapy approach for oligometastasis SBRT in clinical settings, as measured by successful completion of treatment
Measured over Up to 2 weeks (timeframe of SBRT treatment)
+1 more outcome measured

Conditions

Oligometastasis
Oligometastatic Disease

Explore related trials

Oligometastatic Disease

NCT07079098

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center

    Cleveland, Ohiostudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Lauren Henke, MD, MSCI · PRINCIPAL_INVESTIGATOR · Case Comprehensive Cancer Center, University Hospitals

Who to contact

Lauren Henke, MD, MSCI
[email protected]
(218) 234 -6429
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants must have histologically, cytologically, or radiographically or confirmed cancer that is oligometastastatic (defined in this protocol as up to 5 active sites of disease at time of trial enrollment). Note that previous ablative therapy to the treatment site (excluding prior external beam radiation) is permitted, such as previous microwave ablation or radiofrequency ablation.
Age ≥18 years.
Performance status: Eastern Cooperative Oncology Group (ECOG) Performance status ≤ 2
Estimated life expectancy of at least 3 months
Participants must be considered a candidate for SBRT by the treating physician
Prior chemotherapy or biological treatment is allowed, but any active oncological treatment should be stopped at least 1 week prior to radiation therapy and renewed no sooner than 1 week following radiation therapy, with the exception of endocrine therapies, which can continue through radiation treatment.
Participants must have the ability to understand and the willingness to sign a written informed consent document.
Participants must have a diagnostic CT, MRI, or PET/CT of the site(s) intended for treatment, with or without contrast, acquired no more than 30 days prior to study consent.

Exclusion

Prior radiotherapy to any site overlapping with the projected site for protocol treatment.
Participants with isolated vertebral metastases except for sacral spine; participants with osseous spine disease can be treated upon this protocol, but those sites (cervical, thoracic, lumbar spine) are not permitted for treatment upon this study. Such participants could be enrolled for treatment to other, concurrent (e.g., visceral, or non-spine bone) disease on this study.
Pregnant or breastfeeding women are excluded from this study.
Women of childbearing potential must have a negative pregnancy test within 14 days of study entry. If pregnancy test is not clinically indicated as determined by the treating physician or protocol principal investigator (PI), documentation of this exception is sufficient in lieu of a pregnancy test.

What this trial measures

  • Feasibility of a simulation-free adaptive radiotherapy approach for oligometastasis SBRT in clinical settings, as measured by successful completion of treatmentUp to 2 weeks (timeframe of SBRT treatment)

    Successful completion of treatment will be determined by first-fraction radiation delivery occurring in the first on-table treatment attempt for at least 70% of participants with simulation-free plans meeting dosimetric requirements.

  • Feasibility of a simulation-free adaptive radiotherapy approach for oligometastasis SBRT in clinical settings, as measured by pre-treatment quality assurance clinical gamma passing indexUp to 2 weeks (timeframe of SBRT treatment)

    A pre-treatment quality assurance clinical gamma passing index that is less than or equal to 2%/2mm will be considered successful.